A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
NCT04257929
Abnormalities, Multiple, Chromosome Disorders
San Diego, California, United States
View Trial Details